Consensus statement reports clinical utility of molecular drug susceptibility testing in tuberculosis patients, highlighting standardized reporting to guide initial regimens.
Key Points
Single nucleotide mutations in key genomic regions indicate drug resistance in vivo, informing immediate clinical regimens for Mycobacterium tuberculosis.
Review of electronic databases and hand-searched journals identified resistance mutations across seven genes, establishing consensus on molecular drug susceptibility testing.
Highlights the need for comprehensive molecular reports to interpret discordant phenotypic drug resistance and ensure effective initial regimens.